Sword Health is the digital-health company — last valued at roughly $4 billion — that combines licensed physical therapists with AI and motion sensors to deliver musculoskeletal (MSK) care, like physical therapy for back, joint and muscle pain, remotely to employees and health-plan members. It is one of the most prominent virtual-care companies, but as of mid-2026 Sword Health is still private: there is no S-1, no ticker and no IPO price range. This is a “what to watch” breakdown of the Sword Health IPO, plus the publicly traded digital-health stocks you can actually buy today to play the same theme.
Sword Health IPO Snapshot
| Field | Detail |
|---|---|
| Company | Sword Health, Inc. |
| Proposed Ticker / Exchange | TBD / TBD (not disclosed) |
| IPO Status (Phase) | Private; no public S-1 filed (pre-IPO) |
| Expected Price Range | Not disclosed |
| Last Reported Valuation | ~$4 billion (2025 funding round) |
| Business | AI-powered digital physical therapy & MSK care |
| Total Funding Raised | ~$700 million+ (reported) |
| Founder & CEO | Virgílio Bento |
| HQ / Founded | New York / 2015 |
Figures are from press reporting and private financings, not an audited public prospectus. Sword Health has not filed an S-1; treat all numbers as reported estimates subject to change.
Table of Contents
- Key Takeaways
- What Is Sword Health?
- When Will the Sword Health IPO Happen?
- What We Know About Sword Health’s Business & Economics
- Who Are Sword Health’s Competitors?
- Sword Health IPO: Bull Case vs What to Watch
- How Sword Health Is Priced vs Public Peers
- How to Get Exposure to the Sword Health IPO Theme
- Sword Health IPO FAQs
Key Takeaways
- What it does: Sword Health delivers virtual musculoskeletal care — combining physical therapists, AI and motion sensors — so employees and health-plan members can treat back, joint and muscle pain from home, sold mainly to employers and insurers.
- IPO status: The Sword Health IPO is anticipated but unscheduled — the company is private with no S-1, ticker or price range as of mid-2026.
- Key number: Sword Health was last valued around $4 billion in a 2025 round and has expanded across MSK and adjacent care areas.
- What to watch: Competition with Hinge Health, employer-benefit budgets, proving clinical outcomes and ROI, profitability, and the eventual audited financials.
- Exposure angle: You cannot buy Sword Health shares yet; the practical way to trade the digital-health theme is via public peers — Hinge Health, Teladoc, Omada Health, Doximity and Hims & Hers.
What Is Sword Health?
Sword Health is a digital-health company founded in 2015 by Virgílio Bento, with roots in Portugal and headquarters in New York. It focuses on musculoskeletal care — the treatment of pain and injury in muscles, joints and bones, which is one of the largest and most expensive categories of healthcare spending. Sword’s approach pairs licensed physical therapists with an AI “care specialist” and motion-tracking sensors, so a patient can do guided physical-therapy exercises at home while the system tracks their movement, gives real-time feedback, and lets a human therapist oversee progress. Over time, Sword has expanded beyond core MSK into adjacent areas such as pelvic health and other virtual-care programs, positioning itself as a broader digital-care platform.
The thesis behind the Sword Health IPO is that MSK conditions cost employers and insurers enormous sums, that much care can be delivered effectively and more cheaply from home, and that combining clinicians with AI can scale quality care while lowering costs. Sword Health makes money primarily by selling to employers and health plans, which offer its programs as a benefit to employees and members, often with pricing tied to engagement or outcomes. For anyone searching “what is Sword Health” or “is Sword Health going public,” the short answer is: Sword Health is an AI-powered virtual MSK-care company, and the Sword Health IPO is anticipated but not yet filed.
When Will the Sword Health IPO Happen?
There is no official Sword Health IPO date. As a large, well-funded digital-health company — and with its direct rival Hinge Health having gone public — Sword Health is frequently discussed as an eventual IPO candidate, and its leadership has spoken about a listing as a possibility. But as of mid-2026 it has not filed a public S-1, set a price range, named underwriters or announced a timeline, so everything about a listing remains speculative.
The key caveat is that the Sword Health IPO is a watch item, not a scheduled event, and the figures in circulation come from private funding rounds rather than audited filings. Its roughly $4 billion valuation reflects strong growth and investor interest in AI-enabled care; private marks can shift and may not reflect where public markets would price the company, especially given how digital-health stocks have traded since the pandemic-era boom. Timing would likely depend on Sword Health demonstrating durable growth, clinical outcomes and a path to profitability, plus a receptive IPO window. Until Sword Health files an S-1 with audited financials, the responsible stance is to treat the Sword Health IPO as anticipated but unconfirmed.
What We Know About Sword Health’s Business & Economics
Without a prospectus, Sword Health’s financial picture comes from reporting and company statements and should be read as such. The core model is business-to-business: Sword sells its programs to employers and health plans, which provide them to employees and members, typically paying based on enrollment, engagement or measured outcomes. This model can scale efficiently — one platform serving many members — and aligns Sword’s revenue with the value it delivers when pricing is outcome-based. Sword has reported rapid growth and expansion into new care categories, and it emphasizes clinical evidence and cost savings as key selling points to benefits buyers, though exact current financials are not publicly audited.
What the public numbers do not reveal is the detail investors would need: revenue, growth rate, gross margin, engagement and profitability. The central tension for the Sword Health IPO is that digital-health companies must continually prove clinical outcomes and return on investment to win and keep employer and insurer contracts, and public markets have been tough on the sector since many pandemic-era virtual-care stocks fell sharply. Competition — especially with Hinge Health in MSK — is intense. The bullish read is an AI-enabled care platform attacking a huge cost category with strong growth; the cautious read is a company in a demanding, budget-sensitive market where proving durable value and profitability is essential. Those open questions are why this analysis offers no buy or sell verdict on an unlisted company.
Who Are Sword Health’s Competitors?
Sword Health competes in digital MSK and virtual care, where several rivals are public. Hinge Health stock is the most direct comparable — a digital MSK-care company that went public and targets the same employer and health-plan customers with a similar therapist-plus-technology model, making it the clearest public read on Sword’s market. Teladoc Health stock is a broad virtual-care platform whose scale and struggles illustrate how public markets value telehealth.
Omada Health stock is a comparable digital-care company focused on chronic-condition and lifestyle programs sold to employers and plans, and Doximity stock offers exposure to digital-health infrastructure and clinician networks. Hims & Hers stock shows how a consumer-facing digital-health brand scales, a different but related model. Together the listed names form a tradeable map of the digital-health theme the Sword Health IPO highlights.
Correlated & Competitor Stocks
| Company (Ticker) | What they do | Why correlated to Sword Health | Approx. price (early Jun 2026) |
|---|---|---|---|
| Hinge Health (HNGE) | Digital MSK care | Closest direct public comparable | Double digits |
| Teladoc Health (TDOC) | Broad virtual care | Telehealth valuation read-across | Single-to-double digits |
| Omada Health (OMDA) | Digital chronic-care programs | Employer/plan digital-care peer | Double digits |
| Doximity (DOCS) | Clinician network & digital health | Digital-health infrastructure exposure | Double digits |
| Hims & Hers (HIMS) | Consumer digital health | Digital-health scaling comparable | Double digits |
Prices are approximate and as of early June 2026; verify the live quote before trading.
Sword Health IPO: Bull Case vs What to Watch
The bull case. Sword Health attacks musculoskeletal care — one of the largest, most expensive categories of health spending — with a model that pairs clinicians, AI and sensors to deliver effective care from home at lower cost. Selling to employers and health plans gives it a scalable B2B channel, and outcome-linked pricing can align its revenue with the value it delivers. Expansion into adjacent care areas broadens its market, and AI can improve both quality and efficiency over time. If Sword proves strong clinical outcomes and converts growth into profitability, it has the profile of a digital-care leader — the optimistic frame for the Sword Health IPO.
What to watch (rather than a verdict, since Sword Health is private and pre-filing). First, competition with Hinge Health and others for the same employer and plan budgets. Second, proving clinical outcomes and return on investment, which benefits buyers demand. Third, profitability and engagement, which a fresh S-1 would reveal. Fourth, the tough public market for digital-health stocks since the pandemic-era boom faded. Fifth, whether its private valuation holds up in public markets. These are the dynamics to track before the Sword Health IPO becomes investable.
How Sword Health Is Priced vs Public Peers
Because there is no public Sword Health stock, the only yardstick is its last private valuation against listed digital-health names. At roughly $4 billion (set in 2025), Sword Health would be broadly comparable to, or above, its direct rival Hinge Health and other digital-care peers, depending on the day’s prices. Hinge Health is by far the most instructive comparable because it operates in the same digital MSK market with a similar model and now discloses the revenue growth, margins and engagement metrics public markets use to value this exact business. The Sword Health IPO valuation will ultimately hinge on its growth, outcomes and profitability versus these benchmarks.
The honest framing for a Phase-pre-IPO name is “high-growth digital-care company in a sector public markets have repriced.” Many telehealth and digital-health stocks fell sharply after the pandemic-era surge, and investors now scrutinize profitability and durable engagement closely, so Sword Health’s eventual IPO valuation could land above or below its latest private mark depending on conditions and its financials at filing. Until Sword publishes audited numbers, there is no responsible buy or sell call to make on it. What investors can do today is decide how much they believe in the digital-health thesis and express that through the listed peers above, where real prices and financials already exist.
How to Get Exposure to the Sword Health IPO Theme
To be direct: you cannot buy Sword Health shares before it lists, pre-IPO access is generally limited to institutional and accredited investors, and no listing is confirmed. So for most people the realistic question is not “how do I buy Sword Health stock” but “how do I get exposure to the digital-health theme the Sword Health IPO represents.” The practical answer is the basket of public digital-health names above — many available as real U.S. shares through US stocks on MEXC.
A theme-based approach spreads the risk: direct digital MSK care through Hinge Health, broad virtual care through Teladoc, employer-focused chronic-care programs through Omada Health, clinician-network and digital-health infrastructure through Doximity, and consumer digital health through Hims & Hers. These names move on the same drivers that will shape Sword Health — employer and insurer adoption of virtual care, healthcare cost pressures, and the role of AI in delivering care. None is a substitute for owning Sword Health directly, but as a group they let you participate in the digital-health cycle now, with normal liquidity and no allocation lottery. Note this sector has been volatile; confirm live prices and size positions to your own risk tolerance. This is information, not a recommendation.
Sword Health IPO FAQs
What does Sword Health do?
Sword Health delivers virtual musculoskeletal care, combining licensed physical therapists, an AI care specialist and motion sensors so patients can treat back, joint and muscle pain from home. It sells mainly to employers and health plans.
When is the Sword Health IPO?
No date has been set. As of mid-2026 Sword Health is private with no public S-1, underwriters or price range. An IPO is anticipated — especially after rival Hinge Health went public — but it remains a watch item rather than a scheduled event.
Can I buy Sword Health stock before the IPO?
No. Sword Health is private, and pre-IPO shares are generally restricted to institutional and accredited investors. The public will only be able to buy it once (and if) it lists — or get exposure to the theme now through public peers.
What is Sword Health’s valuation?
Sword Health was last valued around $4 billion in a 2025 funding round. That is a private figure, so any eventual IPO valuation could differ materially in either direction depending on its financials and market conditions.
Who are Sword Health’s competitors?
Public competitors and comparables include Hinge Health (its closest direct rival), Teladoc Health, Omada Health, Doximity and Hims & Hers across digital MSK and virtual care.
Disclaimer
This article is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation to buy any security. IPO details (price range, valuation, timing) are subject to change and may differ from the final terms. You cannot purchase shares of a company before it lists, and IPO allocations are not guaranteed. Past performance does not guarantee future results. Investors should read the company’s official SEC filings and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.